30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Sutro Biopharma Inc (STRO)

Track

The most recent insider trading activity occurred on January 20, 2026, with a proposed sale of shares by a former officer. Prior to this, in October 2025, several executives made purchases. The last significant insider selling activity was noted in January 2024.
Stock chart
Ticker: STRO Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
BARBARA LEYMAN
Former Officer
1 sale — total 130,962 USD
Proposed sale 20 Jan 2026
Value US$247,217.16 | Price 477.48 | Shares 18,053
Buy 15 Oct 2025
Value US$197,865.15 | Price 456.57 | Shares 99,103
Planned buy 15 Oct 2025
Value US$9,993.20 | Price 0.80 | Shares 12,504
Buy 15 Oct 2025
Value US$39,950.00 | Price 0.80 | Shares 50,000
Buy 15 Oct 2025
Value US$15,997.50 | Price 0.81 | Shares 19,750
Buy 15 Oct 2025
Value US$10,011.25 | Price 0.80 | Shares 12,500
Planned sale 29 Jan 2024
Value US$60,925.00 | Price 5.00 | Shares 12,185
Proposed sale 29 Jan 2024
Value US$60,925.00 | Price 5.00 | Shares 12,185
Planned sale 28 Aug 2023
Value US$72,594.91 | Price 4.71 | Shares 15,428
Sale 25 Aug 2023
Value US$53,281.61 | Price 4.59 | Shares 11,613
Proposed sale 25 Aug 2023
Value US$156,331.00 | Price 5.78 | Shares 27,041
Buy 14 Mar 2022
Value US$77,508.00 | Price 7.75 | Shares 10,000
Planned sale 28 Sep 2021
Value US$72,724.25 | Price 18.62 | Shares 3,906
Planned sale 26 Jan 2021
Value US$4,306.15 | Price 26.10 | Shares 165
Planned sale 26 Jan 2021
Value US$57,221.72 | Price 25.68 | Shares 2,228
Planned sale 28 Dec 2020
Value US$53,530.21 | Price 22.37 | Shares 2,393
Planned sale 27 Nov 2020
Value US$40,713.07 | Price 17.01 | Shares 2,393
Planned sale 5 Nov 2020
Value US$251,265.00 | Price 15.00 | Shares 16,751
Planned sale 28 Sep 2020
Value US$10,006.72 | Price 10.26 | Shares 975
Sale 18 Sep 2020
Value US$4,800,000.00 | Price 12.00 | Shares 400,000
Sale 11 Sep 2020
Value US$5,000,000.00 | Price 10.00 | Shares 500,000
Planned sale 26 Aug 2020
Value US$8,818.29 | Price 9.04 | Shares 975
Sale 19 Aug 2020
Value US$4,360,000.00 | Price 8.72 | Shares 500,000
Planned sale 27 Jul 2020
Value US$7,858.21 | Price 8.06 | Shares 975
Planned sale 26 May 2020
Value US$9,753.32 | Price 10.00 | Shares 975
Buy 14 May 2020
Value US$499,999.00 | Price 7.75 | Shares 64,516
Buy 14 May 2020
Value US$49,995.25 | Price 7.75 | Shares 6,451
Buy 14 May 2020
Value US$24,993.75 | Price 7.75 | Shares 3,225
Planned sale 27 Apr 2020
Value US$22.38 | Price 11.19 | Shares 2
Planned sale 27 Apr 2020
Value US$9,160.50 | Price 9.41 | Shares 973
Planned sale 26 Mar 2020
Value US$9,452.53 | Price 9.69 | Shares 975
Planned sale 26 Feb 2020
Value US$10,207.28 | Price 10.47 | Shares 975
Planned sale 27 Jan 2020
Value US$10,250.37 | Price 10.51 | Shares 975
Planned sale 26 Dec 2019
Value US$10,802.22 | Price 11.08 | Shares 975
Planned sale 26 Nov 2019
Value US$10,410.27 | Price 10.68 | Shares 975
Planned sale 28 Oct 2019
Value US$9,726.11 | Price 9.98 | Shares 975
Buy 1 Oct 2018
Value US$9,999,990.00 | Price 15.00 | Shares 666,666
Sale 1 Oct 2018
Value US$1,830.00 | Price 15.00 | Shares 122
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-01-20 2026-01-20 PrS Proposed sale
BARBARA LEYMAN

Former Officer

Officer
18,053
477.48
US$247,217 		18,053 477.48 US$247,217
2025-10-16 2025-10-15 B Purchase
3.3
Gerber Hans-Peter

CHIEF SCIENTIFIC OFFICER

Officer
99,103 +25.0%
456.57
US$197,865 		99,103 +25.0% 456.57 US$197,865
2025-10-16 2025-10-15 PP Planned purchase
Pauling David

Chief Admin. Ofcr. & GC

Officer
77,841 -20.9%
127.79
US$851,437 		77,841 -20.9% 127.79 US$851,437
2025-10-16 2025-10-15 B Purchase
2.8
MATSUI CONNIE
Non-Executive Director
50,000 +inf%
0.80
US$39,950 		50,000 +inf% 0.80 US$39,950
2025-10-16 2025-10-15 B Purchase
3.6
Chow Gregory K.

CFO

Officer
19,750 +inf%
0.81
US$15,998 		19,750 +inf% 0.81 US$15,998
2025-10-16 2025-10-15 B Purchase
3.3
Chung Jane

Chief Executive Officer

Executive Director
12,500 +11.3%
0.80
US$10,011 		12,500 +11.3% 0.80 US$10,011
2024-01-31 2024-01-29 PlS Planned sale
Vasquez Nicki

CHIEF PORT. STRAT & ALNCE OFCR

Officer
12,185 -48.8%
5.00
US$60,925 		12,185 -48.8% 5.00 US$60,925
2024-01-29 2024-01-29 PrS Proposed sale
NICKI J VASQUEZ

Officer

Officer
12,185
5.00
US$60,925 		12,185 5.00 US$60,925
2023-08-29 2023-08-28 PlS Planned sale
3.1
Shtylla Brunilda

Chief Business Officer

Officer
15,428 -100.0%
4.71
US$72,595 		15,428 -100.0% 4.71 US$72,595
2023-08-28 2023-08-25 S Sale
3.1
Shtylla Brunilda

Chief Business Officer

Officer
11,613 -47.3%
4.59
US$53,282 		11,613 -47.3% 4.59 US$53,282
2023-08-25 2023-08-25 PrS Proposed sale
3.1
Shtylla Brunilda

Officer

Officer
27,041
5.78
US$156,331 		27,041 5.78 US$156,331
2022-03-15 2022-03-14 B Purchase
3.4
NEWELL WILLIAM J

CEO

Executive Director
10,000 +9.4%
7.75
US$77,508 		10,000 +9.4% 7.75 US$77,508
2021-09-28 2021-09-28 PlS Planned sale
Vasquez Nicki

Chief Port. Strat & Alnce Ofcr

Officer
3,906 -34.9%
18.62
US$72,724 		3,906 -34.9% 18.62 US$72,724
2021-01-27 2021-01-26 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
165 -0.3%
26.10
US$4,306 		165 -0.3% 26.10 US$4,306
2021-01-27 2021-01-26 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
2,228 -3.8%
25.68
US$57,222 		2,228 -3.8% 25.68 US$57,222
2020-12-29 2020-12-28 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
2,393 -6.1%
22.37
US$53,530 		2,393 -6.1% 22.37 US$53,530
2020-11-30 2020-11-27 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
2,393 -6.1%
17.01
US$40,713 		2,393 -6.1% 17.01 US$40,713
2020-11-06 2020-11-05 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
16,751 -31.3%
15.00
US$251,265 		16,751 -31.3% 15.00 US$251,265
2020-09-28 2020-09-28 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
975 -3.4%
10.26
US$10,007 		975 -3.4% 10.26 US$10,007
2020-09-22 2020-09-18 S Sale
2.2
Freund John Gordon
Non-Executive Director
400,000 -41.7%
12.00
US$4,800,000 		400,000 -41.7% 12.00 US$4,800,000
2020-09-15 2020-09-11 S Sale
2.2
Freund John Gordon
Non-Executive Director
500,000 -34.2%
10.00
US$5,000,000 		500,000 -34.2% 10.00 US$5,000,000
2020-08-27 2020-08-26 PlS Planned sale
Hallam Trevor

Chief Scientific Officer

Officer
975 -5.5%
9.04
US$8,818 		975 -5.5% 9.04 US$8,818
2020-08-21 2020-08-19 S Sale
2.2
Freund John Gordon
Non-Executive Director
500,000 -25.5%
8.72
US$4,360,000 		500,000 -25.5% 8.72 US$4,360,000
2020-07-28 2020-07-27 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
975 -5.2%
8.06
US$7,858 		975 -5.2% 8.06 US$7,858
2020-05-27 2020-05-26 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
975 -4.7%
10.00
US$9,753 		975 -4.7% 10.00 US$9,753
2020-05-14 2020-05-14 B Purchase
3.4
NEWELL WILLIAM J

CEO

Executive Director
64,516 +63.2%
7.75
US$499,999 		64,516 +63.2% 7.75 US$499,999
2020-05-14 2020-05-14 B Purchase
3.0
MOLINA ARTURO MD

Chief Medical Officer

Officer
6,451 +114.5%
7.75
US$49,995 		6,451 +114.5% 7.75 US$49,995
2020-05-14 2020-05-14 B Purchase
3.2
FITZPATRICK LINDA A

Chief People & Comm. Officer

Officer
3,225 +55.8%
7.75
US$24,994 		3,225 +55.8% 7.75 US$24,994
2020-04-27 2020-04-27 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
2 -0.0%
11.19
US$22 		2 -0.0% 11.19 US$22
2020-04-27 2020-04-27 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
973 -4.5%
9.41
US$9,161 		973 -4.5% 9.41 US$9,161
2020-03-27 2020-03-26 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
975 -4.3%
9.69
US$9,453 		975 -4.3% 9.69 US$9,453
2020-02-27 2020-02-26 PlS Planned sale
Hallam Trevor

Chief Science Officer

Officer
975 -4.1%
10.47
US$10,207 		975 -4.1% 10.47 US$10,207
2020-01-28 2020-01-27 PlS Planned sale
Hallam Trevor

Chief Science Officer
975 -4.0%
10.51
US$10,250 		975 -4.0% 10.51 US$10,250
2019-12-27 2019-12-26 PlS Planned sale Hallam Trevor

Chief Science Officer

Officer
975 -3.8%
11.08
US$10,802 		975 -3.8% 11.08 US$10,802
2019-11-27 2019-11-26 PlS Planned sale
Hallam Trevor

Chief Science Officer
975 -3.7%
10.68
US$10,410 		975 -3.7% 10.68 US$10,410
2019-10-30 2019-10-28 PlS Planned sale
Hallam Trevor

Chief Science Officer
975 -3.5%
9.98
US$9,726 		975 -3.5% 9.98 US$9,726
2018-10-02 2018-10-01 B Purchase Merck & Co., Inc. Large shareholder
666,666 +32.4%
15.00
US$9,999,990 		666,666 +32.4% 15.00 US$9,999,990
2018-10-01 2018-10-01 S Sale Petree Daniel H Non-Executive Director
122 -38.9%
15.00
US$1,830 		122 -38.9% 15.00 US$1,830
Explore more

More insider trading research around Sutro Biopharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America